Efficacy of allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia adult patients in first complete remission: A meta-analysis of prospective studies

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Li, Dandan ^a,b   Wang, Li ^a,b   Zhu, Honghu ^c   Dou, Liping ^a   Liu, Daihong ^a   Fu, Lin ^d   Ma, Cong ^e   Ma, Xuebin ^e   Yao, Yushi ^a   Zhou, Lei ^a,f   Wang, Qian ^a   Wang, Lijun ^a   Zhao, Yu ^a   Jing, Yu ^a   Wang, Lili ^a   Li, Yonghui ^a   Yu, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Medical College of Chinese PLA ^*  (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d PEKING UNIVERSITY THIRD HOSPITAL   (China)

^e NAVY GENERAL HOSPITAL   (China)

^f No 202 Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; CONSOLIDATION CHEMOTHERAPY; HUMAN; INDUCTION CHEMOTHERAPY; INTERMEDIATE RISK PATIENT; META ANALYSIS; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SYSTEMATIC REVIEW; TREATMENT RELATED MORTALITY; WHOLE BODY RADIATION; ADULT; ALLOTRANSPLANTATION; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; PROPORTIONAL HAZARDS MODEL; REMISSION; RISK; TREATMENT OUTCOME;

ADULT; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84941219651     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132620     Document Type: Article

References (64)

1. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336. PMID: 12393746
2. National Comprehensive Cancer Network. Acute myeloid leukemia, Version 1. 2014. http://www.nccn. org/. Accessed January 30. 2014.
3. Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, et al. Repetitive cycles of highdose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13; q22): Results from CALGB 8461. J Clin Oncol. 2004; 22: 1087-1094. PMID: 15020610
4. Bloomfield CD, Ruppert AS, Mrozek K, Kolitz JE, Moore JO, Mayer RJ, et al. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Ann Hematol. 2004; 83 Suppl 1: S84-85. PMID: 15124687
5. Suciu S, Mandelli F, Witte T, Zittoun R, Gallo E, Labar B, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial Blood, 2003:1232-1240. PMID: 12714526
6. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96: 4075-4083. PMID: 11110676
7. Schlenk RF, Dohner K, Mack S, Stoppel M, Kiraly F, Gotze K, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. Journal of Clinical Oncology. 2010; 28: 4642-4648. doi: 10.1200/JCO.2010.28.6856 PMID: 20805454
8. Ghielmini M. Third International Symposium on recent advances in hematopoietic stem cell transplantation. Clinical progress, new technologies and gene therapy, March 16-18, 1995, San Diego, CA. Ann Oncol. 1995; 6: 533-536. PMID: 8573530
9. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301: 2349-2361. doi: 10.1001/jama.2009.813 PMID: 19509382
10. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2008; 14: 556-567. doi: 10.1016/j.bbmt.2008.02.019 PMID: 18410898
11. Cornelissen JJ, Van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood. 2007; 109: 3658-3666. PMID: 17213292
12. Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK. Long-term results of the MRC AML10 trial Clinical advances in hematology & oncology: H&O, 2006:445-451.
13. Grimwade D. Impact of Cytogenetics on Clinical Outcome in AML. In: Karp J, ed. Acute Myelogenous Leukemia: Humana Press, 2007:177-192.
14. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116: 354-365. doi: 10.1182/blood-2009-11-254441 PMID: 20385793
15. Spellman S, Setterholm M, Maiers M, Noreen H, Oudshoorn M, Fernandez-Vina M, et al. Advances in the selection of HLA-compatible donors: Refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant. 2008; 14: 37-44. doi: 10.1016/j.bbmt.2008.05.001 PMID: 18721779
16. Johansen KA, Schneider JF, McCaffree MA, Woods GL, Council on S, Public Health AMA. Efforts of the United States' National Marrow Donor Program and Registry to improve utilization and representation of minority donors. Transfus Med. 2008; 18: 250-259. doi: 10.1111/j.1365-3148.2008.00865.x PMID: 18783584
17. Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant. 2010; 16: 1541-1548. doi: 10.1016/j.bbmt.2010.08.011 PMID: 20800103
18. Yanik G, Levine JE, Ratanatharathorn V, Dunn R, Ferrara J, Hutchinson RJ. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant. 2000; 26: 161-167. PMID: 10918426
19. Kasper C, Sayer HG, Mugge LO, Schilling K, Scholl S, Issa MC, et al. Combined standard graft-versushost disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant. 2004; 33: 65-69. PMID: 14704658
20. Yanada M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: A clinical perspective. Int J Hematol. 2014.
21. Hubel K, Weingart O, Naumann F, Bohlius J, Fresen MM, Engert A, et al. Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: A systematic analysis of international guidelines and recommendations. Leuk Lymphoma. 2011; 52: 444-457. doi: 10.3109/10428194.2010. 546918 PMID: 21323525
22. GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. NewCastle-Ottawa Quality Assessment Scale-Cohort Studies[EB/OL]. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. 2012-06-15.
23. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. PMID: 17555582
24. Champlin RE, Ho WG, Gale RP, Winston D, Selch M, Mitsuyasu R, et al. Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med. 1985; 102: 285-291. PMID: 3882039
25. Conde E, Iriondo A, Rayon C, Richard C, Fanjul E, Garijo J, et al. Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myelogenous leukaemia in first remission: A prospective controlled trial. Br J Haematol. 1988; 68: 219-226. PMID: 3280005
26. Reiffers J, Gaspard MH, Maraninchi D, Michallet M, Marit G, Stoppa AM, et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: A prospective controlled trial. British Journal of Haematology. 1989; 72: 57-63 PMID: 2660902
27. Lowenberg B, Verdonck LJ, Dekker AW, Willemze R, Zwaan FE, De Planque M, et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: Results of a Dutch prospective study. Journal of Clinical Oncology. 1990; 8: 287-294. PMID: 2405106
28. Ferrant A, Doyen C, Delannoy A, Cornu G, Martiat P, Latinne D, et al. Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission. Bone Marrow Transplant. 1991; 7: 303-309. PMID: 2070137
29. Cassileth PA, Andersen JW, Bennett JM, Harrington DP, Hines JD, Lazarus HM, et al. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: The ECOG experience. The Eastern Cooperative Oncology Group. Leukemia. 1992; 6 Suppl 2: 116-119. PMID: 1578910
30. Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. Journal of Clinical Oncology. 1992; 10: 41-46. PMID: 1727924
31. Archimbaud E, Thomas X, Michallet M, Jaubert J, Troncy J, Guyotat D, et al. Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. Journal of Clinical Oncology. 1994; 12: 262-267. PMID: 8113835
32. Labar B, Mrsic M, Nemet D, Bogdanic V, Radman I, Boban D, et al. Allogenic bone marrow transplantation versus chemotherapy for patients with acute myelogenous leukaemia in first remission. Transplantationsmedizin: Organ Der Deutschen Transplantationsgesellschaft. 1994; 6: 235-239.
33. Hewlett J, Kopecky KJ, Head D, Eyre HJ, Elias L, Kingsbury L, et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): A Southwest oncology group study. Leukemia. 1995; 9: 562-569. PMID: 7723385
34. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995; 332: 217-223. PMID: 7808487
35. Sierra J, Brunet S, Granena A, Olive T, Bueno J, Ribera JM, et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia leukemia. Catalan Group for Bone Marrow Transplantation. J Clin Oncol. 1996; 14: 1353-1363. PMID: 8648394
36. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New England Journal of Medicine. 1998; 339: 1649-1656. PMID: 9834301
37. Keating S, De Witte T, Suciu S, Willemze R, Hayat M, Labar B, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: An analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. British Journal of Haematology. 1998; 102: 1344-1353. PMID: 9753069
38. Brunet S, Esteve J, Berlanga J, Ribera JM, Bueno J, Marti JM, et al. Treatment of primary acute myeloid leukemia: Results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Haematologica. 2004; 89: 940-949. PMID: 15339677
39. Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F, et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intentto-treat long-term analysis of the BGMT experience. Journal of Clinical Oncology. 2005; 23: 7676-7684. PMID: 16186596
40. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1909-1918. doi: 10.1056/NEJMoa074306 PMID: 18450602
41. Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission Leukemia, 2009:635-640. doi: 10.1038/leu.2008.352 PMID: 19151786
42. Mohty M, de Lavallade H, El-Cheikh J, Ladaique P, Faucher C, Furst S, et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: Long term results of a 'donor' versus 'no donor' comparison. Leukemia. 2009; 23: 194-196. doi: 10.1038/leu.2008.164 PMID: 18580956
43. Hospital MA, Thomas X, Castaigne S, Raffoux E, Maury S, Gardin C, et al. Long-term outcome associated with current allogeneic stem cell transplantation procedures in younger adults with adverse-risk AML in first CR-A real-life transplant versus no-transplant analysis of the acute leukemia french association (ALFA). Blood. 2010; 116.
44. Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, et al. Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: Results of the JALSG AML97 study. International Journal of Hematology. 2010; 91: 284-292. doi: 10.1007/s12185-009-0483-2 PMID: 20063133
45. Cornelissen JJ, Gratwohl A, Van Montfort KGM, Pabst T, Maertens J, Beverloo HB, et al. Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) improves outcome as compared to conventional consolidation in patients aged 40-60 years with AML in CR1 with apparent greater benefit for reduced intensity rather than myeloablative conditioning. Blood. 2011; 118.
46. Juliusson G, Karlsson K, Lazarevic VL, Wahlin A, Brune M, Antunovic P, et al. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: Real-World Population-Based Data from the Swedish Acute Leukemia Registry 1997-2006. Cancer. 2011; 117: 4238-4246. doi: 10.1002/cncr.26033 PMID: 21387283
47. Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, et al. Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: Landmark analysis from a single prospective multicenter trial. Haematologica. 2011; 96: 972-979. doi: 10.3324/haematol. 2011.041004 PMID: 21459795
48. Hospital MA, Thomas X, Castaigne S, Raffoux E, Pautas C, Gardin C, et al. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Bone Marrow Transplantation. 2012; 47: 1436-1441. doi: 10.1038/bmt.2012.49 PMID: 22426749
49. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-or high-risk acute myeloid leukemia in first complete remission. Blood. 2012; 119: 5584-5590. doi: 10.1182/blood-2011-11-389809 PMID: 22535659
50. Kayser S, Zucknick M, Dohner K, Krauter J, Kohne CH, Horst HA, et al. Monosomal karyotype in adult acute myeloid leukemia: Prognostic impact and outcome after different treatment strategies. Blood. 2012; 119: 551-558. doi: 10.1182/blood-2011-07-367508 PMID: 22096250
51. Gorin NC, Labopin M, Ciceri F, Piemontese S, Arcese W, Di Bartolomeo P, et al. T repleted haploidentical mismatch allogeneic versus autologous hematopoietic stem cell transplantation in adult patients with acute leukemia in complete remission (CR): A pair-matched analysis from the acute leukemia working party of EBMT. Blood. 2013; 122.
52. Mohr B, Schetelig J, Schäfer-Eckart K, Schmitz N, Hänel M, Rösler W, et al. Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia British journal of haematology, 2013:237-244.
53. Schlenk RF, Taskesen E, Van Norden Y, Krauter J, Ganser A, Bullinger L, et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood. 2013; 122: 1576-1582. doi: 10.1182/blood-2013-05-503847 PMID: 23863898
54. Yoon JH, Kim H, Shin SH, Jeon YW, Kim JH, Lee SE, et al. Molecular and cytogenetic risk stratification for core-binding factor-positive adult AML with analysis of post-remission treatment outcomes including transplantation. Blood. 2013; 122.
55. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997; 90: 2978-2986. PMID: 9376578
56. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer. 2003; 97: 1721-1731. PMID: 12655529
57. Pfirrmann M, Ehninger G, Thiede C, Bornhäuser M, Kramer M, Röllig C, et al. Prediction of post-remission survival in acute myeloid leukaemia: A post-hoc analysis of the AML96 trial The Lancet. Oncology, 2012:207-214. doi: 10.1016/S1470-2045(11)70326-6 PMID: 22197676
58. Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: Results from the AML05 multicenter trial. Blood. 2013; 121: 4056-4062. doi: 10.1182/blood-2012-11-468348 PMID: 23535063
59. Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: A prospective matched pairs analysis. Journal of Clinical Oncology. 2014; 32: 288-296. doi: 10.1200/JCO.2013.50.5768 PMID: 24366930
60. Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: An evidence-based review. Biol Blood Marrow Transplant. 2008; 14: 137-180. doi: 10.1016/j.bbmt.2007. 11.002 PMID: 18215777
61. Levi I, Grotto I, Yerushalmi R, Ben-Bassat I, Shpilberg O. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res. 2004; 28: 605-612. PMID: 15120937
62. Cai X, Wei J, He Y, Yang D, Jiang E, Huang Y, et al. A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies. Int J Clin Pharm. 2015; 37: 44-52. doi: 10.1007/s11096-014-0036-5 PMID: 25432692
63. Abdul Wahid SF, Ismail NA, Mohd-Idris MR, Jamaluddin FW, Tumian N, Sze-Wei EY, et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: A meta-analysis. Stem Cells Dev. 2014; 23: 2535-2552. doi: 10.1089/scd.2014.0123 PMID: 25072307
64. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol. 2002; 118: 385-400. PMID: 12139722